Tatva Chintan Pharma Chem: Final Dividend for FY26 & TDS Intimation
Tatva Chintan Pharma Chem recommended a final dividend of ₹2.00 per share for FY 2025-26. The company has issued detailed guidelines on Tax Deduction at Source (TDS) for resident and non-resident shareholders. Shareholders must submit necessary documentation by September 10, 2026, to ensure correct tax withholding or claim exemptions.
This is a standard procedural announcement related to dividend distribution and tax compliance. It does not introduce any new strategic initiatives, financial results, or major corporate actions that would significantly impact the company's valuation or operations.
The announcement is a routine communication regarding dividend payout and associated tax regulations. It provides necessary information to shareholders but does not contain any new financial performance data or significant business developments.
Tatva Chintan Pharma Chem Limited has issued a communication to its shareholders regarding the final dividend for the financial year 2025-26 and the associated Tax Deduction at Source (TDS) or withholding tax. The Board of Directors, in a meeting held on May 16, 2026, recommended a final dividend of ₹2.00 per equity share (20%) for FY 2025-26. This recommendation is subject to approval by the shareholders at the upcoming 30th Annual General Meeting (AGM).
The company has detailed the process and documentation required for shareholders to claim tax exemption or understand the withholding tax rates on the dividend. For resident shareholders, TDS will generally be deducted at 10%, unless exempt. Specific conditions apply for resident individuals, with TDS not applicable if the aggregate dividend does not exceed ₹10,000. Shareholders can provide Form 121 to claim exemptions, provided eligibility conditions are met. Failure to provide valid PAN or linking it with Aadhaar may result in TDS at 20%.
NIL or lower tax deduction is possible for certain resident shareholders, including insurance companies, mutual funds, Alternative Investment Funds (AIFs), New Pension System Trust, and others, upon submission of specific declarations and supporting documents. For non-resident shareholders, tax will be withheld at 20% (plus applicable surcharge and cess), unless beneficial Double Tax Avoidance Agreement (DTAA) provisions are availed. This requires submission of a Tax Residency Certificate (TRC), Form 41, and a self-declaration regarding Permanent Establishment in India, among other documents.
The company has provided links to download necessary forms and declarations. Shareholders are urged to update their details with depositories or the Registrar and Transfer Agent (MUFG Intime India Private Limited) by September 10, 2026, to ensure correct TDS determination. Updates to bank account details are also requested to facilitate direct dividend credit.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.